Indefinite Delivery Contract SPE2DR25D9787

The key products and services being delivered under this federal Indefinite Delivery Contract (IDC) awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc. are a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. The IDC, valued at $499,999,999 and valid through November 2026, covers an extensive portfolio of pharmaceutical products including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables across various product categories such as injections, tablets, creams, auto-injectors, and specialty medications. This single-award IDC enables the DLA to issue firm fixed-price delivery orders for these pharmaceutical items to meet the recurring medical supply requirements of the Department of Defense (DoD) healthcare sites, as well as the United States Coast Guard, Designated Providers, and Other Government Agencies. The contract was competitively awarded on an unrestricted basis, without any set-aside designations, allowing DMS Pharmaceutical Group to leverage its status as a woman-owned small business to secure this significant prime award with the DLA.

The original federal contract opportunity was part of the DLA Troop Support Medical Supply Chain's plan to establish Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) contracts to provide worldwide pharmaceutical support to various DoD customers. The solicitation, expected to be issued in March 2024, will seek multiple primary supplier awards for separate geographic regions as well as a single backup supplier award, with the intent of ensuring resiliency and access to vital pharmaceuticals during contingencies or natural disasters. The total estimated value for all regions and options is $30.3 billion, and the awards will be made on a lowest price technically acceptable (LPTA) basis, with the potential use of a reverse auction to obtain the best distribution fees.